Latest News


European BioArtists featured in Online Exhibition by Pioneering New York Platform

SciArt Center, a New York-based organisation for the collaboration of scientists and artists on all manner of endeavours, has just opened an online exhibition of bioart featuring a number of European artists. The exhibit, titled, “EmBodied,” explores the understanding of …


Good news for Mylan after Dramatic Week: an Opportunity in MS drugs

In the middle of a pricing maelstrom, there is some good news for Mylan: the US PTO has validated its challenges to Copaxone patents, which could unlock Teva’s MS drug market share.  Mylan has not had a good week. It’s …


US Money Magnet get hands on UK Bispecific Antibodies for Neurodegenerative Disease

F-star’s “plug-and-play” technology can turn any existing antibody into a full-size bispecific antibody. Denali has recognized its potential use for drug delivery to the CNS and inked a deal with the UK-based company for almost €1B. Denali (US) and F-Star …

Memo Therapeutic map header

Antibodyomes for faster Discovery of Biologicals, with Memo Therapeutics

After delighting ourselves with fabulous French gastronomy in Nancy, it’s time to say our farewells and head to the next border. Basel is our final destination. Our goal? Get to know a bit more of Swiss-based company Memo Therapeutics, our …


UCL & Cell Medica start a TCR Collaboration towards a Cancer Cure

Bridging the divide between academia and industry, Cell Medica and UCL are teaming up on TCR engineering in the effort to find a cancer cure. Not many details were disclosed, but cancer now has a new force to reckon with. …


Novartis is Favoured to Win the Race for a New MS Drug

Novartis is poised to kick off the next generation of multiple sclerosis treatments after siponimod performs well in Phase III. The company’s primary competitor had been Biogen, but its drug’s failure in Phase II leaves siponimod the last man standing. Novartis reports …


Daratumumab could Knock Multiple Myeloma Down and Out: EMA will Judge

Multiple Myeloma is almost a death sentence: you probably won’t make it through five more years, and even if current treatments send it to remission, your chances of relapse are high. Janssen’s new drug, Darzalex (daratumumab), has shown promise to …


Galapagos Hangs On: Filgotinib enters Phase III for Rheumatoid Arthritis

After losing AbbVie as a partner, Galapagos has pressed on with Gilead in the development of filgotinib for rheumatoid arthritis. Phase III trials have officially begun! Galapagos is making progress as its rheumatoid arthritis drug, filgotinib, enters Phase III clinical …


Cold Sore Season is Coming! AiCuris might have a Herpes Cure

Cold sores plagued 67% of people under 50 in 2012. AiCuris is developing a cure, Pritelivir, and it just cleared Phase I trials. It could be superior to treatments currently on the market. Cold sores, known as recurrent labial herpes …

HIV-infected H9 T-cell

While working on its HIV Cure, Gilead gives Europe an ‘HIV Vaccine’

Despite progress in HIV treatments and towards an HIV cure, the infection rate has risen to unprecedented levels in Europe. Gilead’s HIV-1 ‘vaccine’, Truvada, has just been approved for marketing in Europe to stop its spread. The year 2014 brought …

jobs header 2482016

Fancy moving to Sweden or Switzerland? Chalmers University and Actelion have jobs for you!

We’re back once again with a carefully curated list of jobs based in Europe just for you! Have a look, choose wisely, apply and maybe you can kickstart your career within the Biotech and Pharmaceutical industry! Good luck! Research and …


€350M CRISPR Joint Venture now has a Name and an Office

Bayer and CRISPR Therapeutics have invested $373M in a joint venture, Casebia, as the latest effort to bring the revolutionary gene editing technology to the medical market. This brainchild represents a huge leap of faith, since no preliminary results have …


Inside Labiotech


Curious about the Labiotech Refresh backstage? Look behind the scenes!

It’s been four months since we put together the most Refreshing biotech conference in Europe. We got over a 150 attendees and they recommend it at 100%. We are now working on the next Labiotech Refresh, but first, let’s have a look on what …


It’s still Summer, snatch a Special Deal for Labiotech Refresh!

Yes, we have a special summer price for the next Labiotech Refresh event in Paris! It will be held on November 24th with 250 Biotech leaders from all across Europe in an awesome location (yes, super awesome but still secret for …


Event Planning

Don't miss the hottest European Biotech News!